Table IV.
Role of UCA1 in tumor drug resistance.
| Cancer type | Drug resistance | Mechanisms | (Refs.) |
|---|---|---|---|
| PDAC | 5-FU | UCA1 promotes EMT by activating the AKT and ERK signaling pathways in PDAC cells | (16) |
| Bladder cancer | Cisplatin/gemcitabine | UCA1 inhibits cisplatin/gemcitabine-induced apoptosis via targeting p27Kip1 | (70) |
| Bladder cancer | Cisplatin | UCA1 upregulates Wnt6 expression | (12) |
| Bladder cancer | Multidrug resistance | UCA1 inhibits autophagy by upregulating ATG7 expression | (21) |
| OC | Paclitaxel | UCA1 upregulates ABCB1 expression | (128) |
| CRC | 5-FU | UCA1 upregulates CREB1 expression | (22) |
| AML | Adriamycin | UCA1 upregulates the HK2 expression | (129) |
| BC | Tamoxifen | UCA1 activates the mTOR signaling pathway | (74) |
| BC | Tamoxifen | UCA1 activates the Wnt/β-catenin signaling pathway | (83) |
| BC | Trastuzumab | UCA1 upregulates YAP1 expression | (131) |
| Glioma | Cisplatin/temozolomide | UCA1 activates the Wnt/β-catenin signaling pathway | (81) |
| CRC | Cetuximab | UCA1 in exosomes transmits cetuximab resistance | (130) |
| CML | Imatinib | UCA1 upregulates MDR1 expression | (132) |
| PCa | Docetaxel | UCA1 upregulates Sirt1 expression | (133) |
| Retinoblastoma | Multidrug resistance | UCA1 upregulates STMN1 expression | (127) |
UCA1, urothelial carcinoma associated 1; 5-FU, 5-fluorouracil; AML, acute myeloid leukemia; BC, breast cancer; CML, chronic myeloid leukemia; CRC, colorectal cancer; CREB1, cAMP response element-binding protein 1; HK2, hexokinase 2; MDR1, multidrug resistance protein 1; mTOR, mammalian target of rapamycin; OC, ovarian cancer; PCa, prostate cancer; PDAC, pancreatic ductal adenocarcinoma; STMN1, stathmin 1; YAP1, yes-associated protein 1.